肺癌基因组检测市场：依技术、检测类型、应用和最终用户划分－2026-2032年全球市场预测

预计到 2025 年，肺癌基因组检测市场价值将达到 11.6 亿美元，到 2026 年将成长到 12.6 亿美元，到 2032 年将达到 20.7 亿美元，复合年增长率为 8.58%。

主要市场统计数据
基准年 2025	11.6亿美元
预计年份：2026年	12.6亿美元
预测年份 2032	20.7亿美元
复合年增长率 (%)	8.58%

全面概述了技术进步及其在临床实践中的应用如何重新定义肺癌基因组检测并塑造治疗路径。

目前，肺癌基因组检测正处于临床紧迫性和技术能力的交汇点，它正在重塑诊断、治疗方案製定和转化研究。随着分子层面的洞察力日益成为标靶治疗治疗和免疫疗法适用性的关键因素，临床医生和检查室正在采用基因组检测，从基于组织学的诊疗模式转向以精准医学主导的治疗路径。因此，病理学、分子生物学、生物资讯学和临床肿瘤学等以往各自独立的领域正在融合，从而构建出整合的诊疗路径，缩短患者接受标靶治疗的时间，并实现更精准的患者分层。

定序、液态生物检体和数位生物资讯学的融合如何迅速改变肺癌治疗的诊断途径和患者管理。

肺癌基因组检测领域正经历多项变革，主要得益于检测技术、数据分析和医疗服务模式的进步。尤其值得一提的是，次世代定序已从高成本、以研究为导向的工作流程，发展成为更高效、经临床检验的平台，支持透过全外EXOME和全基因组方法以及靶向定序panel实现广泛的基因组覆盖。这项进展使临床医生能够检测到罕见突变和全面的基因组特征，同时检查室也能优化处理能力和反应时间。

近期关税压力对供应链的影响如何重塑了基因组诊断领域的采购、製造策略和商业性模式。

近期各国政策制定者实施的关税调整，使得诊断生态系内的供应链韧性与筹资策略再次受到重视。由于基因组检测依赖全球供应链取得试剂、定序设备、塑胶耗材和专用微流体组件，因此关税导致的成本增加会对检查室营运、试剂采购週期和资本设备购置决策产生连锁反应。因此，检查室和诊断服务提供者必须重新评估供应商合约、库存策略和资本投资计划，以确保服务的连续性并维持可接受的检测结果回应时间。

以细分市场为中心的洞察，展示了技术选择、检体模式、临床应用和最终用户能力如何共同决定采用路径和价值提案。

从详细的市场细分观点，不同技术、检测类型、应用和终端用户类别之间的引入模式呈现出微妙的变化，从而塑造了市场机会和投资重点。从技术层面来看，检测方法涵盖了萤光原位杂合反应、微阵列平台、即时聚合酵素链锁反应和桑格定序等。然而，次世代定序正迅速崛起，成为一项至关重要的技术，其配置也多种多样。这些配置包括针对特定可操作突变的标靶定序panel、用于全面分析转录区的全EXOME定序，以及用于检测最广泛的突变并获得结构资讯的全基因测序。每种配置在灵敏度、覆盖范围、週转时间和结果解读的复杂度方面都各有优劣。

影响技术采用、偿还努力和策略伙伴关係的区域部署趋势和基础设施考量。

区域趋势对技术应用、监管协调和商业策略产生了重大影响，美洲、欧洲、中东和非洲以及亚太地区呈现不同的模式。在美洲，由学术机构、综合医疗保健系统和诊断技术创新者组成的强大生态系统推动了先进基因组分析和液态生物检体检测的早期临床应用。该地区的报销框架和大规模临床研究正在促进伴随诊断融入治疗路径，同时领先的实验室和商业合作伙伴也持续投资于平台扩充性和临床检验计画。

定序设备製造商、试剂供应商、诊断检测实验室和生物製药合作伙伴如何协调其策略以实现临床准入和商业性差异化。

肺癌基因组检测价值链的竞争主要集中在以下几类公司之间：提供定序平台、检测试剂、综合诊断服务和临床解读解决方案的公司，以及将检测和治疗方案结合的临床实验室和诊断开发公司。领先的仪器供应商正致力于制定以通量、运行成本和整合分析能力为重点的平台蓝图，而试剂和试剂盒供应商则在稳健性、批间一致性和简化监管申报和检查室认证流程的临床检验方案方面展开竞争。

为企业提供切实可行的建议，以增强供应链韧性，加快证据生成，并确保与支付方和合作伙伴合作，以实现永续成长。

产业领导企业应优先采取一系列切实可行、以证据为基础的措施，在应对技术复杂性、政策变化和市场压力的同时，创造临床和商业性价值。首先，他们必须实现价值链多元化，并透过本地化生产和对关税敏感的试剂和耗材采用第二供应商合约来稳定采购成本。同时，他们应投资于检测方法优化，以最大限度地减少试剂用量并简化工作流程，从而保持盈利能力和韧性。

透明、多方面的研究途径，结合与专家的直接参与和系统性的证据审查，确保了严谨且可操作的见解。

本分析的基础研究采用了一种多方面的方法，将一手定性研究与系统的二手资讯分析相结合，建构了一个稳健且多方验证的证据基础。一手研究包括对临床实验室管理人员、分子病理学家、医保报销专家、诊断药物研发人员以及製药公司研发负责人进行结构化访谈，并辅以专家专题研讨会，以检验检测实施中的新兴趋势和实际挑战。这些工作深入分析了检查室工作流程、采购趋势以及监管和关税变化对营运的影响。

简要概述如何将技术进步与策略挑战相结合，并将基因组检测转化为可持续的临床和商业性影响。

先进定序技术、液态生物检体创新和数位化分析工具的融合，为肺癌基因组检测的临床格局带来了不可逆转的改变。这些进步既带来了机会，也带来了挑战。机会包括能够更精准地选择治疗方法、支持适应性临床试验以及透过微创检测实现时间序列监测。另一方面，挑战包括需要策略远见的供应链管理、证据产生以及与保险公司的合作。因此，决策者必须采取综合观点，协调技术投资、临床检验和商业性部署。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 市场进入策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肺癌基因组检测市场：依技术划分

• 萤光原位杂合反应
• 微阵列
• 次世代定序
  • 目标序列
  • 全EXOME定序
  • 全基因组定序
• 即时聚合酵素链锁反应
• 桑格定序

第九章 肺癌基因组检测市场：检测类型

• 液态生物检体
  • 循环性肿瘤细胞
  • 循环肿瘤DNA
• 组织切片检查
  • 细针穿刺
  • 组织切片

第十章：肺癌基因组检测市场：依应用领域划分

• 伴随诊断
• 预测性测试
• 预后检查
• 治疗监测

第十一章 肺癌基因组检测市场：依最终用户划分

• 学术研究机构
• 医院和诊断检测实验室
• 製药和生物技术公司

第十二章 肺癌基因组检测市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 肺癌基因组检测市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 肺癌基因组检测市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章：美国肺癌基因组检测市场

第十六章：中国肺癌基因组检测市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• Admera Health
• Agilent Technologies, Inc.
• BGI
• CD Genomics
• CeGaT GmbH
• Centogene NV
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories
• OncoDNA
• OPKO Health, Inc.
• QIAGEN NV
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific, Inc.
• Veracyte, Inc.

The Lung Cancer Genomic Testing Market was valued at USD 1.16 billion in 2025 and is projected to grow to USD 1.26 billion in 2026, with a CAGR of 8.58%, reaching USD 2.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.16 billion
Estimated Year [2026]	USD 1.26 billion
Forecast Year [2032]	USD 2.07 billion
CAGR (%)	8.58%

A comprehensive orientation to how technological advances and clinical integration are redefining lung cancer genomic testing and shaping care pathways

Lung cancer genomic testing now sits at the intersection of clinical urgency and technological capability, reshaping diagnostics, therapeutic decision-making, and translational research. As molecular insights increasingly determine targeted therapies and immunotherapy candidacy, clinicians and laboratories are adopting genomic assays to move from histology-based care to precision-guided treatment pathways. In consequence, previously discrete disciplines-pathology, molecular biology, bioinformatics, and clinical oncology-are converging to deliver integrated care pathways that reduce time to targeted therapy and enable more nuanced patient stratification.

Moreover, the testing landscape is evolving from single-gene assays to multi-gene panels and comprehensive genomic profiling that capture actionable mutations, copy number alterations, and complex genomic signatures. Complementing tissue-based approaches, minimally invasive alternatives such as blood-based testing are accelerating diagnostic workflows and improving patient access to serial monitoring. At the same time, regulatory clarity, payer engagement, and clinical guideline updates are beginning to align, making genomic testing a central component of standard care in many oncology networks. Taken together, these dynamics have created a new operating environment where technological differentiation, evidence generation, and operational resilience determine which organizations lead the next wave of clinical and commercial adoption.

How converging advances in sequencing, liquid biopsy, and digital bioinformatics are rapidly transforming diagnostic pathways and patient management in lung cancer care

The landscape of lung cancer genomic testing is undergoing several transformative shifts driven by advances in assay technology, data analytics, and care delivery models. Most notably, next generation sequencing has evolved from high-cost, research-oriented workflows toward more efficient, clinically validated platforms that support targeted sequencing panels as well as broader coverage through whole exome and whole genome approaches. This progression enables clinicians to detect rare variants and comprehensive genomic signatures while laboratories optimize throughput and turnaround time.

In parallel, liquid biopsy methodologies-encompassing both circulating tumor cells and circulating tumor DNA-are transitioning from complementary tools to integral components of diagnostic and monitoring strategies. These assays offer a less invasive route to capture tumor heterogeneity and to monitor treatment response or emergent resistance. Meanwhile, real time polymerase chain reaction and fluorescence in situ hybridization maintain important roles for specific, rapid biomarker detection, particularly where regulatory or payer frameworks favor established methods.

Concurrently, digital health and AI-driven bioinformatics have matured to support automated variant calling, clinical annotation, and decision support, thereby reducing interpretation bottlenecks and enabling scalable reporting across diverse clinical settings. Regulatory agencies are adapting guidance for companion diagnostics and complex genomic tests, and payers are increasingly evaluating clinical utility and value-based reimbursement pathways. Together, these shifts are creating a more integrated, data-rich ecosystem that rewards evidence generation, interoperability, and operational agility.

How recent tariff-driven supply chain pressures have reshaped procurement, manufacturing strategies, and commercial approaches for genomic diagnostics

Recent tariff adjustments enacted by national policymakers have introduced a renewed emphasis on supply chain resilience and procurement strategy within the diagnostic ecosystem. Because genomic testing relies on a global supply chain for reagents, sequencing instruments, plastic consumables, and specialized microfluidic components, any tariff-driven cost increases reverberate through laboratory operations, reagent procurement cycles, and capital equipment acquisition decisions. As a result, laboratories and diagnostic providers have had to reassess vendor contracts, inventory strategies, and capital planning to preserve service continuity and to maintain acceptable turnaround times.

In response, several stakeholders have explored alternative sourcing and local manufacturing partnerships to mitigate exposure to import levies and shipping volatility. Procurement teams are negotiating longer-term supply agreements and prioritizing suppliers with diversified production footprints to reduce single-source risk. At the same time, diagnostic developers are accelerating work on assay designs that reduce reagent volumes or substitute tariff-sensitive components, thereby lowering the operational impact of import duties.

From a clinical perspective, sustained cost pressure may slow the adoption of more expensive, comprehensive testing in some care settings unless offset by payer coverage or bundled contracting. Consequently, laboratories and device manufacturers are investing in health economic evidence and real-world utility studies to demonstrate cost-effectiveness and inform value-based arrangements. Overall, tariff-driven pressures are catalyzing a strategic reorientation toward supply-chain diversification, localized manufacturing, and commercially sustainable assay design.

Segment-focused insights showing how technology choices, specimen modalities, clinical applications, and end-user capabilities jointly determine adoption pathways and value propositions

A detailed segmentation perspective reveals nuanced adoption patterns across technology, test type, application, and end user categories that are shaping market opportunity and investment priorities. Within the technology dimension, assays range from fluorescence in situ hybridization and microarray platforms to real time polymerase chain reaction and Sanger sequencing; however, next generation sequencing has emerged as a pivotal technology with diverse configurations that include targeted sequencing panels for focused actionable alterations, whole exome sequencing for comprehensive coding-region analysis, and whole genome sequencing for the broadest possible variant detection and structural insight. Each configuration carries distinct trade-offs in sensitivity, breadth of coverage, turnaround time, and interpretive complexity.

Regarding test type, the domain divides between liquid biopsy and tissue biopsy modalities. Liquid biopsy comprises both circulating tumor cells and circulating tumor DNA approaches, offering minimally invasive sampling and superior feasibility for serial monitoring. Tissue biopsy remains essential for histopathologic assessment and includes fine needle aspiration techniques as well as traditional tissue sections used for immunohistochemistry and confirmatory molecular assays. These two sampling paradigms often play complementary roles in the diagnostic pathway, with diagnostic stewardship determining optimal sequencing of tests.

In terms of application, testing supports companion diagnostics that directly guide therapy selection, predictive testing to anticipate treatment response, prognostic testing to inform outcome expectations, and treatment monitoring to detect resistance or recurrence. Adoption intensity varies by clinical setting, evidence base, and payer alignment. Finally, end users encompass academic and research institutes that drive assay validation and translational studies, hospitals and diagnostic laboratories that deliver clinical testing at scale and manage patient workflows, and pharmaceutical and biotechnology companies that rely on robust genomic characterization to support drug development, companion diagnostic partnerships, and patient selection strategies. The interplay among these segments underscores the importance of tailored value propositions, from high-throughput clinical laboratory services to niche translational platforms supporting drug discovery.

Regionally differentiated adoption dynamics and infrastructure considerations that influence technology roll-out, reimbursement engagement, and strategic partnerships

Regional dynamics materially influence technology adoption, regulatory alignment, and commercial strategy, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a robust ecosystem of academic centers, integrated health systems, and diagnostic innovators has driven early clinical adoption of advanced genomic profiling and liquid biopsy testing. Reimbursement frameworks and large-scale clinical studies in this region have supported the integration of companion diagnostics into therapeutic pathways, while leading laboratories and commercial partners continue to invest in platform scalability and clinical validation programs.

Across Europe, the Middle East and Africa, the landscape is more heterogeneous, characterized by strong regulatory oversight in several countries alongside variability in access and infrastructure. European jurisdictions are increasingly harmonizing regulatory expectations for clinical evidence and companion diagnostics, and collaborative networks are advancing multicenter studies to address clinical utility questions. In contrast, access in some parts of the Middle East and Africa remains constrained by laboratory capacity and reimbursement barriers, prompting a focus on regional centers of excellence and public-private partnerships to extend advanced testing services.

In the Asia-Pacific region, rapid expansion in clinical capacity and manufacturing capabilities is evident alongside diverse payer environments. Several markets demonstrate high adoption rates for both sequencing platforms and liquid biopsy testing, supported by growing local diagnostics industries and targeted investments in genomics. Nevertheless, adoption is uneven, and strategic players often combine centralized high-complexity testing hubs with decentralized sample collection and digital reporting to bridge geographic and resource constraints. These regional distinctions underline the need for market entry strategies that reflect local regulatory processes, reimbursement pathways, and healthcare infrastructure.

How sequencing instrument makers, reagent suppliers, diagnostic laboratories, and biopharma partners are aligning strategies to gain clinical adoption and commercial differentiation

Competitive activity across the lung cancer genomic testing value chain is concentrated among companies that provide sequencing platforms, assay reagents, integrated diagnostic services, and clinical interpretation solutions, as well as among clinical laboratories and diagnostics developers who pair testing with therapeutic programs. Leading instrumentation providers have advanced platform roadmaps focused on throughput, run cost, and integrated analytics, while reagent and kit suppliers compete on robustness, lot-to-lot consistency, and clinical validation packages that simplify regulatory submissions and laboratory accreditation.

Diagnostic laboratories and specialty providers leverage vertical integration, offering end-to-end services from sample accessioning to clinical reporting, often augmenting their offerings with proprietary bioinformatics pipelines and curated variant databases. Pharmaceutical and biotechnology collaborators prioritize partners that can deliver rapid, reproducible genomic characterization to support patient selection in trials and companion diagnostic co-development. Strategic moves such as partnerships, distribution agreements, and targeted acquisitions are common as companies seek to broaden assay portfolios, enhance geographic footprint, and reduce time to market for diagnostic claims.

To remain competitive, organizations increasingly invest in real-world evidence generation, payor engagement, and interoperability with electronic health records to demonstrate clinical utility and to facilitate clinician adoption. Additionally, companies that offer scalable, cloud-enabled interpretation tools and that maintain high standards for clinical validation are best positioned to capture demand from both centralized reference laboratories and decentralized hospital networks.

Action-oriented recommendations for companies to strengthen supply resilience, accelerate evidence generation, and secure payer and partner alignment for sustainable growth

Industry leaders should prioritize a set of pragmatic, evidence-based actions to navigate technological complexity, policy shifts, and market pressures while capturing clinical and commercial value. First, diversify supply chains and pursue localized manufacturing or second-source agreements for tariff-sensitive reagents and consumables to reduce single-point vulnerabilities and to stabilize procurement costs. Parallel to this, invest in assay optimization that minimizes reagent volumes and streamlines workflows to preserve margins and resilience.

Second, accelerate clinical validation and real-world evidence programs that demonstrate clinical utility and health economic value. Robust outcome datasets will strengthen reimbursement negotiations and support placement of comprehensive genomic profiling in standard care pathways. Third, expand capabilities in bioinformatics and AI-driven interpretation to shorten report turnaround time, improve variant classification consistency, and enable scalable clinical decision support that integrates with electronic health systems. Fourth, cultivate payer relationships and explore value-based contracting that ties reimbursement to demonstrable clinical outcomes, thereby aligning incentives across stakeholders.

Fifth, form strategic partnerships with pharmaceutical developers to co-develop companion diagnostics and to secure trial enrollment through biomarker-driven screening. Finally, tailor market access strategies regionally by aligning product claims and evidence packages with local regulatory expectations and by deploying hybrid models that combine centralized high-complexity testing with facilitated sample logistics and remote reporting to broaden access.

A transparent multi-method research approach combining primary expert engagement and systematic evidence review to ensure rigorous and actionable insights

The research underlying this analysis employed a multi-method approach that combined primary qualitative inquiry with systematic secondary intelligence to build a robust and triangulated evidence base. Primary research included structured interviews with clinical laboratory directors, molecular pathologists, reimbursement specialists, diagnostic developers, and pharmaceutical R&D leaders, supplemented by expert panel discussions to validate emerging trends and practical challenges in assay deployment. These engagements provided granular insight into laboratory workflows, procurement dynamics, and the operational impact of regulatory and tariff changes.

Secondary research entailed a rigorous review of regulatory guidance documents, clinical practice recommendations, peer-reviewed literature on assay performance and utility, and corporate disclosures that elucidate strategic priorities and product capabilities. Data synthesis prioritized high-quality clinical validation studies and real-world evidence where available. All findings were cross-validated through triangulation to reconcile differing perspectives and to ensure that conclusions reflect consistent signals rather than isolated observations.

Where appropriate, analytical safeguards were applied to account for variability in care settings and regional policy environments. Methodological limitations were explicitly noted, particularly where evidence remains nascent or practice patterns are rapidly evolving. The research adhered to ethical standards for expert engagement and data handling, ensuring confidentiality and the integrity of qualitative insights.

A concise synthesis of how technological advances and strategic imperatives must be aligned to translate genomic testing into durable clinical and commercial impact

The convergence of advanced sequencing technologies, liquid biopsy innovations, and digital interpretation tools has irreversibly altered the clinical landscape for lung cancer genomic testing. These developments present both opportunities and challenges: opportunities to enable more precise treatment selection, to support adaptive clinical trials, and to deliver longitudinal monitoring with minimally invasive tests; and challenges in supply-chain management, evidence generation, and payer engagement that require strategic foresight. Decision-makers must therefore adopt an integrated view that aligns technological investment, clinical validation, and commercial pathways.

Effective responses will blend operational resilience with evidence-led commercialization. By diversifying supply sources, investing in compact and cost-efficient assays, and demonstrating clinical and economic value through robust studies, stakeholders can reduce exposure to policy and market shocks while accelerating adoption. At the same time, regionally nuanced strategies that respect local regulatory norms and healthcare infrastructures will be essential for converting global potential into sustainable clinical impact. In sum, the era of precision oncology in lung cancer depends on harmonized action across industry, clinical, and regulatory stakeholders to translate technical capability into improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

• 8.1. Fluorescence In Situ Hybridization
• 8.2. Microarray
• 8.3. Next Generation Sequencing
  • 8.3.1. Targeted Sequencing
  • 8.3.2. Whole Exome Sequencing
  • 8.3.3. Whole Genome Sequencing
• 8.4. Real Time Polymerase Chain Reaction
• 8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

• 9.1. Liquid Biopsy
  • 9.1.1. Circulating Tumor Cells
  • 9.1.2. Circulating Tumor Dna
• 9.2. Tissue Biopsy
  • 9.2.1. Fine Needle Aspiration
  • 9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

• 10.1. Companion Diagnostics
• 10.2. Predictive Testing
• 10.3. Prognostic Testing
• 10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Hospitals And Diagnostic Laboratories
• 11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Lung Cancer Genomic Testing Market

16. China Lung Cancer Genomic Testing Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Admera Health
• 17.7. Agilent Technologies, Inc.
• 17.8. BGI
• 17.9. CD Genomics
• 17.10. CeGaT GmbH
• 17.11. Centogene N.V.
• 17.12. F. Hoffmann-La Roche AG
• 17.13. Illumina, Inc.
• 17.14. Laboratory Corporation of America Holdings
• 17.15. NeoGenomics Laboratories
• 17.16. OncoDNA
• 17.17. OPKO Health, Inc.
• 17.18. QIAGEN N.V.
• 17.19. Quest Diagnostics Incorporated
• 17.20. Thermo Fisher Scientific, Inc.
• 17.21. Veracyte, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 74. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 75. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 76. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 77. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 78. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 79. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 80. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 81. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 83. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 84. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 86. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 88. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 89. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 91. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 92. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 94. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 96. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 105. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 107. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 108. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 109. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 110. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 111. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 113. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 114. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 115. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 116. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 117. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 118. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 120. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 121. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 122. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 123. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 124. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 125. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 126. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 127. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 128. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 129. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 131. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 132. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 133. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 134. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 135. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 136. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 138. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 139. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 140. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 141. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 142. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 143. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 144. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 145. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 146. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 148. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 149. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 150. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 151. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 152. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 153. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 154. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 155. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 156. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 157. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 158. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 159. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 160. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 161. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 162. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 163. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 164. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 165. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 166. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 167. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 168. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 169. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 170. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 171. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 172. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 173. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 174. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 175. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 176. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 177. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 178. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 179. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 180. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 181. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 182. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 183. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 184. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 185. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 186. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 187. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 188. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 189. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 190. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 191. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 192. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 193. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 194. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 195. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 196. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 197. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 198. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 199. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
• TABLE 200. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
• TABLE 201. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 202. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)